GV-19 |
GVAPG |
CFU-MEG |
||
This peptide, EARPALLTSRLRFIPK, is derived from human TERT [telomerase reverse transcriptase] and corresponds to hTERT(611-626) [telomerase reverse transcriptase(611-626)]. GV1001 is a telomerase-specific, promiscuous class II peptide vaccine which is currently in clinical development as a vaccine against various types of cancers (Shaw et al, 2010).
Lee et al (2013) have reported that, in addition to its own anti-cancer activity, the peptide acts as a cell-penetrating peptide and may be of utility as a carrier for the delivery of macromolecular therapeutics into cells.
GV1001 has been shown to interact with
...
...
...
...
... Subscribe to continue reading!
... ...
Content view restricted ! |